Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 14/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26099980 | 0.85 | USP2 (0.46) | MGLLUSP2SMN1; SMN2RECQLNAMPT | |
| SCHEMBL20025275 | 0.82 | USP2 (0.50) | MGLLUSP2SMN1; SMN2RECQLNAMPT | |
| SCHEMBL26100629 | 0.80 | USP2 (0.40) | MGLLUSP2SMN1; SMN2RECQL | |
| SCHEMBL24803194 | 0.79 | USP2 (0.54) | MGLLUSP2SMN1; SMN2RECQLNAMPT | |
| SCHEMBL2960741 | 0.79 | USP2 (0.51) | MGLLUSP2SMN1; SMN2RECQLNAMPT | |
| SCHEMBL18053621 | 0.78 | USP2 (0.59) | MGLLUSP2SMN1; SMN2RECQL | |
| SCHEMBL17324842 | 0.78 | MGLL (0.70) | MGLLUSP2 | |
| SCHEMBL23121330 | 0.78 | USP2 (0.47) | USP2SMN1; SMN2RECQL | |
| SCHEMBL17328259 | 0.77 | RECQL (0.59) | MGLLUSP2SMN1; SMN2RECQLNAMPT | |
| SCHEMBL30898111 | 0.77 | MGLL (0.42) | MGLLUSP2SMN1; SMN2NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731309-A1 | KRAS PROTEOLYSIS TARGETING CHIMERAS | Paq Therapeutics Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-3886904-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-12404285-B2 | KRAS G12D proteolysis targeting chimeras | PAQ Therapeutics Inc. (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| US-20250114461-A1 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-04-10 | — | — | US | disclosed |
| US-12258341-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| EP-4519273-A1 | KRAS G12D PROTEOLYSIS TARGETING CHIMERAS | Paq Therapeutics Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| US-20250051364-A1 | KRAS G12D Proteolysis Targeting Chimeras | PAQ Therapeutics Inc. (US) | 2025-02-13 | — | — | US | disclosed |
| WO-2024263586-A1 | KRAS PROTEOLYSIS TARGETING CHIMERAS | PAQ Therapeutics Inc. (US) | 2024-12-26 | — | — | WO | disclosed |
| US-12097261-B2 | CDK2 degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-09-24 | — | — | US | disclosed |
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
| EP-3886904-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2021-10-06 | — | — | EP | disclosed |
| CN-113423427-A | IRAK degrading agents and uses thereof | 凯麦拉医疗公司 | 2021-09-21 | — | — | CN | disclosed |
| US-11117889-B1 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-11117889-B1 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| WO-2021053495-A1 | BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2021-03-25 | — | — | WO | disclosed |
| WO-2021053495-A1 | BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2021-03-25 | — | — | WO | disclosed |
| WO-2020113233-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12258341-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | MGLL 1244/4885USP2 141/4885SMN1; SMN2 2647/4885 |
| US-20250051364-A1 | KRAS G12D Proteolysis Targeting Chimeras | KRAS, NRAS, HRAS | MGLL 2573/4885USP2 243/4885SMN1; SMN2 2558/4885 |
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | MGLL 1244/4885USP2 141/4885SMN1; SMN2 2647/4885 |
| US-12404285-B2 | KRAS G12D proteolysis targeting chimeras | KRAS, NRAS, HRAS | MGLL 2573/4885USP2 243/4885SMN1; SMN2 2558/4885 |
| US-11117889-B1 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | MGLL 1244/4885USP2 141/4885SMN1; SMN2 2647/4885 |
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | MGLL 1244/4885USP2 141/4885SMN1; SMN2 2647/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | MGLL 1244/4885USP2 141/4885SMN1; SMN2 2647/4885 |
| US-12097261-B2 | CDK2 degraders and uses thereof | CDK2, CDK20, CDK1 | MGLL 3902/4885USP2 618/4885SMN1; SMN2 2737/4885 |
| US-20250114461-A1 | CDK2 DEGRADERS AND USES THEREOF | CDK2, CDK20, CDK1 | MGLL 3902/4885USP2 618/4885SMN1; SMN2 2737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.